ACE ImmunoID

Neoantigen Identification
for Immuno-Oncology

ACE Services for Immuno-Oncology 2016-12-03T06:23:55+00:00

ACE ImmunoID
Neoantigen Identification for Immuno-Oncology

A singular solution to obtain the most comprehensive genomic and transcriptomic data for neoantigen identification

Key Features and Benefits

  • Augmented targeted sequencing to improve accuracy over coverage gaps present in typical exomes for improved detection of true somatic mutations in tumor
  • DNA and RNA isolated from the same tissue sample to maximize the data generated from precious patient samples
  • Gene expression analysis enabling identification of targets for immune checkpoint blockade
  • Comprehensive profiling and reporting of SNVs, indels, CNAs, gene expression, and novel fusion events
  • GCP compliant, CLIA certified, and CAP accredited laboratory to ensure compliance with clinical laboratory regulations

The ACE Exome® and ACE Transcriptome

The ACE Exome and ACE Transcriptome form the foundation of ACE ImmunoID Neoantigen Identification. Our ACE assays utilize an augmented exome and transcriptome, which supplement coverage of over 8,000 biomedically important genes, including over 1,600 cancer-related genes. This augmentation enables variants to be identified more accurately and reliably in regions that may be completely missed by a typical exome or transcriptome.

A Better Exome for Neoantigen Identification

The Personalis ACE Exome provides targeted sequencing to augment coverage gaps present in typical exomes. For example, the PRDX5 gene is reported to harbor variants that result in immunogenic epitopes, the part of an antigen recognized by the immune system. The illustration below highlights superior, uniform coverage of exonic regions with the ACE Exome (green) compared to the most widely used standard exome (blue) for clinical and translational research. Variants residing in green regions (red rectangles) would be missed with a standard exome platform. ACE Exome assays allow accurate detection of true somatic mutations in tumors to guide neoantigen identification, especially in difficult genomic regions, such as regions with high guanine-cytosine (GC) content.
PRDX5 Sequence Chart_150914

A Better Transcriptome for Neoantigen Identification

Observing the expression of mutated sequences identified using the ACE Exome is key to discerning the peptides that are foreign to the immune system—the neoantigens. RNA is extracted from the tissue sample at the same time as the DNA used for exome sequencing, maximizing the data generated from limited and precious patient samples. ACE Transcriptome sequencing provides data complementary to that provided by the ACE Exome, including gene expression levels, variants in expressed genes, fusion transcripts, and allelic expression. Comparison of variants identified in RNA and DNA, from the same sample, makes it clear which DNA variants are actually expressed in the tumor, and at what level.

Regulatory Compliance

The Personalis laboratory is Good Clinical Practice (GCP) compliant, Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited to ensure compliance with clinical laboratory regulations.